Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of Sacituzumab Govitecan for Patients with Triple Negative Metastatic Breast Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for triple negative metastatic breast cancer, a type of breast cancer that does not have three common receptors known to fuel most breast cancer growths. The treatment being tested is called sacituzumab govitecan, also known by its code name IMMU-132. This medication is a special type of drug called an antibody-drug conjugate, which combines an antibody with a chemotherapy drug to target and kill cancer cells more effectively.

The purpose of the study is to evaluate how well sacituzumab govitecan works in treating patients with this specific type of breast cancer. Participants in the study will receive the medication through an intravenous infusion, which means it will be administered directly into a vein. The study will monitor the participants' response to the treatment over time, looking for any changes in the size or spread of the cancer. The study will also assess the safety of the medication by keeping track of any side effects experienced by the participants.

Throughout the study, participants will have regular check-ups and imaging tests to see how the cancer is responding to the treatment. These tests will help doctors determine if the medication is effective in shrinking the tumors or stopping their growth. The study aims to provide valuable information about the potential benefits and risks of using sacituzumab govitecan for treating triple negative metastatic breast cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the trial, you will be required to sign a written informed consent form. This document confirms your agreement to participate and your understanding of the trial procedures.

    If you are unable to sign the consent form yourself, a trusted person of your choice can sign on your behalf.

  2. Step 2

    Initial assessments

    Before starting the treatment, several assessments will be conducted to ensure you meet the trial's eligibility criteria. These assessments include blood tests to check your blood cell counts, liver and kidney function, and other health indicators.

    A pregnancy test will be conducted for women of childbearing potential. You will also need to confirm your post-menopausal status or provide a negative pregnancy test result.

  3. Step 3

    Treatment administration

    The treatment involves receiving a medication called sacituzumab govitecan, which is administered as an intravenous infusion. This means the medication is given through a needle placed in a vein.

    The dosage and frequency of the medication will be determined by the trial protocol, and you will receive detailed instructions from the medical team.

  4. Step 4

    Regular monitoring

    Throughout the trial, you will have regular visits to monitor your health and the effects of the treatment. These visits will include physical examinations, blood tests, and imaging studies to assess the response of your cancer to the treatment.

    The primary goal is to evaluate the effectiveness of the treatment and to monitor for any side effects.

  5. Step 5

    Biopsy procedures

    You will be asked to undergo biopsy procedures before, during, and after the treatment. A biopsy involves taking a small sample of tissue from your tumor to study the effects of the treatment at a cellular level.

    The biopsy will be performed on a metastatic site that is easily accessible, unless it is a bone metastasis. If the primary tumor site is accessible and has not been previously irradiated, it may be used for the biopsy.

  6. Step 6

    End of treatment

    At the end of the treatment period, a final assessment will be conducted to evaluate the overall response to the treatment and to document any changes in your condition.

    You will receive guidance on follow-up care and any additional steps that may be necessary based on the trial's findings.

Who can join the trial?

21 criteria

  • The patient must have signed a written informed consent before any trial-specific procedures. If the patient is unable to give written consent, a trusted person can confirm the patient's consent in writing.
  • The patient must have adequate blood and organ function:
    • Hemoglobin (a protein in red blood cells) must be at least 9 g/dL.
    • Absolute neutrophil count (a type of white blood cell) must be at least 1500/mm3 or 1.5 x 109/L.
    • Platelets (cells that help with blood clotting) must be at least 100,000/μL without recent transfusions or growth factor support.
    • Creatinine clearance (a measure of kidney function) must be at least 30 mL/min.
    • AST and ALT (liver enzymes) must be no more than 2.5 times the upper limit of normal, or 5 times if there are liver metastases.
    • Total bilirubin (a substance made by the liver) must be no more than 1.5 times the upper limit of normal, or 3 times if there is Gilbert's Syndrome or liver metastases.
    • Serum albumin (a protein in the blood) must be more than 3 g/dL.
    • The patient must have a negative hepatitis B surface antigen test and a negative hepatitis C virus antibody test, or a negative hepatitis C RNA test if the antibody test is positive.
    • Female patients must show evidence of being post-menopausal or have a negative pregnancy test before starting the study treatment.
    • Women of childbearing potential and male patients must agree to use adequate contraception during the trial and for a period after completing treatment (6 months for women, 3 months for men).
    • The patient must be affiliated with a social security system or equivalent.
    • The patient must be willing and able to follow the trial protocol, including treatment, scheduled visits, and examinations.
    • The patient must be at least 18 years old.
    • The patient must have triple negative breast cancer that is locally advanced and inoperable or has spread to other parts of the body. The disease must have progressed after certain treatments.
    • The patient must have been previously treated with a taxane (a type of chemotherapy drug).
    • The patient must have measurable disease as defined by specific criteria (RECIST v1.1).
    • The patient must agree to have biopsies (tissue samples) taken before, during, and after treatment.
    • The patient must have a metastatic site (cancer that has spread) that is easy to biopsy, except for bone metastasis.
    • The patient must have an ECOG performance status of 0, 1, or 2, which measures the ability to perform daily activities.
    • The patient must have a life expectancy of at least 12 weeks.

Who cannot join the trial?

6 criteria

  • Patients who have not been diagnosed with triple negative metastatic breast cancer cannot participate.
  • Patients whose disease has not progressed on first-line chemotherapy for locally advanced breast cancer or metastatic disease are excluded.
  • Patients who have not received (neo)adjuvant chemotherapy for early triple negative breast cancer or whose disease did not progress within 6 months after the end of curative treatments are excluded.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not part of the specified clinical trial groups are excluded.
  • Patients who are not considered part of the vulnerable population selected for the study cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sacituzumab Govitecan is a type of medication used in this clinical trial to treat patients with a specific kind of breast cancer known as triple-negative metastatic breast cancer. This medication is designed to target and attach to cancer cells, delivering a powerful drug directly to them. This helps to kill the cancer cells while trying to limit damage to normal, healthy cells. The goal of using sacituzumab govitecan in this trial is to see how well it works in shrinking tumors or stopping them from growing in patients whose cancer has returned or continued to grow after previous treatments.

What is already known about the treatment

Sacituzumab govitecan – Sacituzumab govitecan is administered as an intravenous infusion, meaning it is given directly into the bloodstream through a vein. It is currently being studied in clinical trials for its effectiveness in treating triple negative metastatic breast cancer, a type of cancer that has spread and does not respond to hormonal therapy. This medication works by targeting a specific protein on cancer cells and delivering a toxic substance to kill them, helping to slow down or stop the growth of the cancer. It is classified as an antibody-drug conjugate, which is a type of targeted cancer therapy.

Investigated diseases

Triple Negative Metastatic Breast Cancer – This is a type of breast cancer that lacks three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER2 protein. It is considered more aggressive than other types of breast cancer because it grows and spreads faster. The disease often progresses quickly, with cancer cells spreading to other parts of the body, such as the bones, liver, or lungs. As it advances, patients may experience symptoms like pain, fatigue, and weight loss. The absence of these receptors means that common hormonal therapies are ineffective, making treatment options more limited. The progression of the disease is typically monitored through imaging tests to assess the spread and growth of tumors.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502369-10-00Protocol codeUC-BCG-2204Estimated enrolment48 patientsSponsorUnicancer

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.